Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 4/20 | 0.51 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | HTR2C | P28335 | 6/20 | 0.46 |
| ▸ | HTR7 | P34969 | 6/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3482958 | 0.98 | PTGES (0.53) | PTGESTAS2R14KDM4EMEN1ALDH1A1 | |
| SCHEMBL12077868 | 0.81 | TAS2R14 (0.52) | PTGESTAS2R14KDM4EMEN1ALDH1A1 | |
| SCHEMBL9657376 | 0.79 | APOBEC3G (0.52) | TAS2R14MEN1ALDH1A1KMT2ACNR2 | |
| SCHEMBL14493759 | 0.76 | MAPK1 (0.54) | PTGESTAS2R14KDM4EMEN1ALDH1A1 | |
| SCHEMBL3482970 | 0.74 | MEN1 (0.61) | KDM4EMEN1ALDH1A1KMT2AHTR2A | |
| SCHEMBL1531674 | 0.74 | PTGES (0.53) | PTGESTAS2R14KDM4EMEN1ALDH1A1 | |
| SCHEMBL3483273 | 0.73 | MEN1 (0.64) | KDM4EMEN1ALDH1A1KMT2AHTR2A | |
| SCHEMBL3482749 | 0.73 | LMNA (0.57) | MEN1ALDH1A1KMT2ACNR2ESR1 | |
| SCHEMBL13251300 | 0.73 | TAS2R14 (0.43) | PTGESTAS2R14KDM4EMEN1ALDH1A1 | |
| Bicarbonate SCHEMBL9058314 | 0.72 | PTGES (0.48) | PTGESTAS2R14KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006225-B2 | Stable pharmaceutical composition | ASAHI KASEI PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| CN-103211811-A | Stable pharmaceutical composition | ASAHI KASEI PHARMA CORP | 2013-07-24 | — | — | CN | disclosed |
| CN-101932317-B | Stable pharmaceutical composition | ASAHI KASEI PHARMA CORP | 2013-03-27 | — | — | CN | disclosed |
| CN-101932317-A | Stable pharmaceutical composition | ASAHI KASEI PHARMA CORP | 2010-12-29 | — | — | CN | disclosed |
| EP-2236135-A1 | STABLE PHARMACEUTICAL COMPOSITION | Asahi Kasei Pharma Corporation (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100041725-A1 | STABLE PHARMACEUTICAL COMPOSITION | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| CN-101410366-A | Substituted bicyclic ring derivatives and uses thereof | ASAHI KASEI PHARMA CORP (JP) | 2009-04-15 | — | — | CN | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| CN-101031539-A | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORP (JP) | 2007-09-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | PTGES 9/4885TAS2R14 4069/4885KDM4E 2981/4885 |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | PTGES 18/4885TAS2R14 3348/4885KDM4E 1472/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | PTGES 18/4885TAS2R14 3348/4885KDM4E 1472/4885 |
| US-20100041725-A1 | STABLE PHARMACEUTICAL COMPOSITION | SLC5A1, SLC5A2, SLC2A9 | PTGES 3800/4885TAS2R14 1865/4885KDM4E 3917/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | PTGES 18/4885TAS2R14 3348/4885KDM4E 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.